Recursion Pharmaceuticals (RXRX) Receivables - Other (2021 - 2025)
Recursion Pharmaceuticals' Receivables - Other history spans 5 years, with the latest figure at $24.6 million for Q4 2025.
- For Q4 2025, Receivables - Other fell 49.87% year-over-year to $24.6 million; the TTM value through Dec 2025 reached $24.6 million, down 49.87%, while the annual FY2025 figure was $24.6 million, 212.01% up from the prior year.
- Receivables - Other reached $24.6 million in Q4 2025 per RXRX's latest filing, up from $21.9 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $49.2 million in Q4 2024 to a low of $2.1 million in Q1 2023.
- Average Receivables - Other over 5 years is $10.4 million, with a median of $6.6 million recorded in 2023.
- Peak YoY movement for Receivables - Other: plummeted 81.9% in 2023, then soared 1489.08% in 2024.
- A 5-year view of Receivables - Other shows it stood at $9.1 million in 2021, then plummeted by 69.6% to $2.8 million in 2022, then rose by 12.39% to $3.1 million in 2023, then skyrocketed by 1489.08% to $49.2 million in 2024, then plummeted by 49.87% to $24.6 million in 2025.
- Per Business Quant, the three most recent readings for RXRX's Receivables - Other are $24.6 million (Q4 2025), $21.9 million (Q3 2025), and $5.9 million (Q2 2025).